Average Co-Inventor Count = 4.33
ph-index = 7
The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.
Company Filing History:
1. University of Pennsylvania (21 from 2,597 patents)
2. Novartis Ag (7 from 3,923 patents)
3. University of Pittsburgh (3 from 1,863 patents)
4. The Wistar Institute (3 from 243 patents)
5. Guedan Carrio, Sonia (0 patent)
21 patents:
1. 12350334 - Compositions and methods for generating a persisting population of T cells useful for the treatment of cancer
2. 12234274 - Use of the CD2 signaling domain in second-generation chimeric antigen receptors
3. 11958892 - Use of ICOS-based cars to enhance antitumor activity and car persistence
4. 11865167 - Treatment of cancer using humanized anti-EGFRvIII chimeric antigen receptor
5. 11718685 - Compositions and methods for targeting stromal cells for the treatment of cancer
6. 11597754 - Use of the CD2 signaling domain in second-generation chimeric antigen receptors
7. 11299536 - Compositions and methods for generating a persisting population of T cells useful for the treatment of cancer
8. 11028177 - Effective targeting of primary human leukemia using anti-CD123 chimeric antigen receptor engineered T cells
9. 10927184 - Treatment of cancer using humanized anti-CD19 chimeric antigen receptor
10. 10800840 - Compositions and methods for generating a persisting population of T cells useful for the treatment of cancer
11. 10577407 - Use of ICOS-based CARS to enhance antitumor activity and CAR persistence
12. 10501519 - Use of the CD2 signaling domain in second-generation chimeric antigen receptors
13. 10329355 - Compositions and methods for targeting stromal cells for the treatment of cancer
14. 10308717 - Treatment of cancer using humanized anti-EGFRvIII chimeric antigen receptor
15. 10221245 - Treatment of cancer using humanized anti-CD19 chimeric antigen receptor